Publications by authors named "C I Busard"
Article Synopsis
- The study investigates how combining methotrexate with adalimumab treatment affects drug concentration and response in psoriasis patients.
- A population PK-PD model was created from data collected over 49 weeks from 59 patients, revealing that methotrexate cotreatment reduces the development of antidrug antibodies, which can enhance the effectiveness of adalimumab.
- Overall, the findings suggest that using methotrexate alongside adalimumab can lead to better treatment outcomes by increasing adalimumab levels and potentially improving clinical responses.
Article Synopsis
- Anti-drug antibodies (ADA) can form in patients treated with adalimumab (ADL), potentially reducing its effectiveness; using methotrexate (MTX) alongside ADL seems to lower ADA levels and improve outcomes in rheumatologic diseases.
- A study was conducted in the Netherlands and Belgium to compare the long-term effectiveness and safety of ADL combined with MTX versus ADL alone over three years in patients with moderate to severe plaque psoriasis.
- Results showed no significant difference in drug survival between the two groups, even though the ADL + MTX group had a trend towards longer survival; however, adverse events led to common discontinuation in the combination group.
Article Synopsis
- Adalimumab is often used with methotrexate (MTX) for better treatment of rheumatoid arthritis and this study aimed to explore its effectiveness for chronic plaque psoriasis.
- The trial compared two groups: one receiving adalimumab alone and the other receiving adalimumab with MTX, analyzing factors like drug survival, response rates, and levels of antidrug antibodies.
- Results showed that the combination therapy led to fewer antidrug antibodies and a trend towards improved treatment response and drug survival, with no significant safety issues reported.
Background: Ustekinumab for the treatment of psoriasis is currently administered in a standard dosing regimen. However, some patients tend to benefit from alternative dosing regimens, a step toward personalized medicine.
Methods: To investigate the role of ustekinumab serum concentrations, anti-ustekinumab antibodies [AUA] and HLA-Cw6 status as tools for optimizing ustekinumab treatment, a multicenter prospective cohort study was conducted at an academic hospital with affiliated nonacademic hospitals in Belgium (cohort 1) and 2 academic hospitals in the Netherlands (cohort 2 and 3).